1
Collection
Collection
Glp-1
Links related to glucagon-like peptide-1 physiology, signaling, and receptor agonists.
What FoundMyFitness Has Covered
PremiumGLP-1 is a gut-derived satiety signal, and GLP-1 receptor agonists mimic it to increase glucose-dependent insulin signaling, reduce glucagon, slow gastric emptying, and influence appetite pathways in the brain. Their effects may extend beyond weight loss…
Your Premium Brief connects insights across FoundMyFitness to help you see the bigger picture.
2
Clip
Clip
Rethinking GLP-1 Drugs for Weight Loss and Long-Term Health
“A separate large cohort analysis found comparable rates of suicide death, self-harm, depression, and anxiety across GLP-1 and comparator treatments. GLP-1 is a gut-derived satiety signal.”
3
Clip
Clip
How GLP-1 Drugs Support Weight Loss and Their Tradeoffs
“In this member Q&A clip, Dr. Rhonda Patrick explains the incretin hormones GIP and GLP-1. GLP-1 receptor agonists such as semaglutide increase glucose-dependent insulin signaling, reduce glucagon, slow gastric emptying, and act on appetite pathways in the brain.”
4
Q&A
Q&A
Premium
Q&A #66: GLP-1 Agonists Beyond Weight Loss—Brain, Heart, Addiction, & Muscle Preservation
Dr. Rhonda Patrick discusses GLP-1 agonists, alpha-lipoic acid, ubiquinone vs. ubiquinol, calcium needs, and liquid biopsy cancer screening.
5
Topic
Topic
Biological Age Clocks
“The result may tell us less about GLP-1 drugs as direct "anti-aging" agents and more about the extent to which correcting metabolic dysfunction can move epigenetic aging clocks. Can AI build better aging clocks?”
6
Science Digest
GLP-1 receptor agonists may lower risks for major illnesses like dementia and seizures.
“Ozempic, Wegovy, and other glucagon-like peptide-1 (GLP-1) drugs have catapulted into the mainstream of diabetes care, with more than 15 million people in the U.S. currently taking one. Evidence suggests GLP-1 drugs have many off-target effects—both good and bad—but healthcare providers don't currently know the full extent of the drugs' effects.”
7
Science Digest
GLP-1 receptor agonists, commonly prescribed for diabetes and weight loss, potentially double the risk of developing the most severe form of age-related macular degeneration.
“A recent study found that glucagon-like peptide-1 (GLP-1) receptor agonists, such as Ozempic, Wegovy, or others, may double the risk of developing neovascular age-related macular degeneration, the most serious form of the disease.”
8
Science Digest
Late-life treatment with the GLP-1 receptor agonist semaglutide extended lifespan, preserved physical function, and improved memory in female mice.
“Comparable reductions in body weight achieved with semaglutide or reduced access to food did not produce the same health benefits. Because GLP-1 receptors are found throughout the body, semaglutide may influence how tissues age in ways that go beyond reducing food intake.”
9
Episode
Episode
Dr. Ben Bikman: How To Reverse Insulin Resistance Through Diet, Exercise, & Sleep
“Are We Using Weight Loss Drugs Wrong? Dr. Ben Bikman is worried about the long-term effects of GLP-1 receptor agonists (GLP-1 RAs) such as Ozempic and Wegovy. GLP-1 is a natural gut-produced hormone, and modern drugs mimic the effects of GLP-1 in the body.”
10
Science Digest
Older adults receiving the GLP-1 agonist semaglutide showed less worsening in a protein-based dementia forecast than those receiving placebo.
“The drug mimics GLP-1, a hormone that helps the pancreas release insulin and the brain regulate appetite. But certain cells in the heart, blood vessels, and other tissues also carry GLP-1 receptors, allowing them to respond to the same signal.”
Results 1–10 of 82